Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis

It has been extensively proved that the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy in advanced non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. However, the question of whether the e...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-09, Vol.9 (9), p.e107161-e107161
Main Authors: Zhang, Yaxiong, Sheng, Jin, Kang, Shiyang, Fang, Wenfeng, Yan, Yue, Hu, Zhihuang, Hong, Shaodong, Wu, Xuan, Qin, Tao, Liang, Wenhua, Zhang, Li
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Chemotherapy
Clinical trials
Clonal deletion
Collaboration
Correlation analysis
Cytotoxicity
Disease-Free Survival
Epidermal growth factor
Epidermal growth factor receptors
Erlotinib Hydrochloride
Gene deletion
Humans
Kinases
Laboratories
Lung cancer
Lung diseases
Medical research
Medicine
Medicine and Health Sciences
Meta-analysis
Metastasis
Mutation
Non-small cell lung carcinoma
Oncology
Patients
Proportional Hazards Models
Protein-tyrosine kinase
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - genetics
Statistical methods
Survival
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been extensively proved that the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy in advanced non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. However, the question of whether the efficacy of EGFR-TKIs differs between exon 19 deletion and exon 21 L858R mutation has not been yet statistically answered. Subgroup data on hazard ratio (HR) for progression-free survival (PFS) of correlative studies were extracted and synthesized based on random-effect model. Comparison of outcomes between specific mutations was estimated through indirect and direct methods, respectively. A total of 13 studies of advanced NSCLC patients with either 19 or 21 exon alteration receiving first-line EGFR-TKIs were included. Based on the data from six clinical trials for indirect meta-analysis, the pooled HRTKI/chemotherapy for PFS were 0.28 (95% CI 0.20-0.38, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0107161